Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender Women

NCT06446752 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06446752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06446752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender Women
Lead sponsor
University of Washington
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 14, 2024
Completion date
January 31, 2027
Enrollment
1,100 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gonorrhea, gonorrhea of anus, gonorrhea of cervix, gonorrhea of pharynx